| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Department of Pathology and Laboratory Medicine,* University of Pennsylvania Medical Center, Philadelphia, Pennsylvania; the Department of Medicine, Huron Hospital, Cleveland Clinic Health System, Cleveland, Ohio; the Department of Obstetrics and Gynecology, Walter Reed Army Medical Center, Washington, D.C.; and the Department of Neurology, Uniformed Services University of the Health Sciences, Bethesda, Maryland
Tissue hypoxia is a characteristic property of cervical cancers that makes tumors resistant to chemo- and radiation therapy. Erythropoietin (Epo) is a hypoxia-inducible stimulator of erythropoiesis. Acting via its receptor (EpoR), Epo up-regulates bcl-2 and inhibits apoptosis of erythroid cells and rescues neurons from hypoxic damage. In addition to human papillomavirus infection, increased bcl-2 expression and decreased apoptosis are thought to play a role in the progression of cervical neoplasia. Using reverse transcriptase-polymerase chain reaction and Western blotting we showed that HeLa and SiHa cervical carcinoma cells and human cervical carcinomas express EpoR, and that hypoxia enhances EpoR expression. Exogenous Epo stimulated tyrosine phosphorylation and inhibited the cytotoxic effect of cisplatin in HeLa cervical carcinoma cells. Using immunohistochemistry, we examined the expression of Epo, EpoR, p16, hypoxia-inducible factor (HIF)-1
, and bcl-2 in benign and dysplastic cervical squamous epithelia and invasive squamous cell carcinomas (ISCCs). EpoR expression in benign epithelia was confined to the basal cell layers, whereas in dysplasias it increasingly appeared in more superficial cell layers and showed a significant correlation with severity of dysplasia. Diffuse EpoR expression was found in all ISCCs. Expression of Epo and HIF-1 was increased in dysplasias compared to benign epithelia. Focal Epo and HIF-1 expression was seen near necrotic areas in ISCCs, and showed correlation in their spatial distribution. Significant correlation was found between expression of EpoR, and p16 and bcl-2 in benign and dysplastic squamous epithelia. Our results suggest that increased expression of Epo and EpoR may play a significant role in cervical carcinogenesis and tumor progression. Hypoxia-inducible Epo signaling may play a significant role in the aggressive behavior and treatment resistance of hypoxic cervical cancers.
This article has been cited by other articles:
 |
|
 |
|
  A. M. Chabowska, M. Sulkowska, A. Chabowski, A. Wincewicz, M. Koda, and S. Sulkowski Erythropoietin and Erythropoietin Receptor in Colorectal Cancer International Journal of Surgical Pathology, July 1, 2008; 16(3): 269 - 276. [Abstract] [PDF]
|
|
|
|
 |
|
 K. A. May and F. R. Khuri Unraveling the Mystery of Erythropoietin-Stimulating Agents in Cancer Promotion Cancer Res., June 1, 2008; 68(11): 4013 - 4017. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. N. Hamadmad and R. J. Hohl Erythropoietin Stimulates Cancer Cell Migration and Activates RhoA Protein through a Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase-Dependent Mechanism J. Pharmacol. Exp. Ther., March 1, 2008; 324(3): 1227 - 1233. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. May and F. R. Khuri Role of Erythropoietin-stimulating Agents in the Outcomes of Patients with Cancer ASCO Educational Book, January 1, 2008; 2008(1): 140 - 144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Saintigny, B. Besse, P. Callard, A.-C. Vergnaud, S. Czernichow, M. Colombat, P. Girard, P. Validire, J.-L. Breau, J.-F. Bernaudin, et al. Erythropoietin and Erythropoietin Receptor Coexpression Is Associated with Poor Survival in Stage I Non Small Cell Lung Cancer Clin. Cancer Res., August 15, 2007; 13(16): 4825 - 4831. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Kokhaei, A. O. Abdalla, L. Hansson, E. Mikaelsson, M. Kubbies, A. Haselbeck, H. Jernberg-Wiklund, H. Mellstedt, and A. Osterborg Expression of Erythropoietin Receptor and In vitro Functional Effects of Epoetins in B-Cell Malignancies Clin. Cancer Res., June 15, 2007; 13(12): 3536 - 3544. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. M. Brown, P. Maxwell, A. N.J. Graham, A. Yakkundi, E. A. Dunlop, Z. Shi, P. G. Johnston, and T. R.J. Lappin Erythropoietin Receptor Expression in Non-Small Cell Lung Carcinoma: A Question of Antibody Specificity Stem Cells, March 1, 2007; 25(3): 718 - 722. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Tanaka, M. Yamamoto, N. Hashimoto, M. Miyakoshi, S. Tamakawa, M. Yoshie, Y. Tokusashi, K. Yokoyama, Y. Yaginuma, and K. Ogawa Hypoxia-Independent Overexpression of Hypoxia-Inducible Factor 1{alpha} as an Early Change in Mouse Hepatocarcinogenesis Cancer Res., December 1, 2006; 66(23): 11263 - 11270. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Leo, L.-C. Horn, C. Rauscher, B. Hentschel, A. Liebmann, G. Hildebrandt, and M. Hockel Expression of Erythropoietin and Erythropoietin Receptor in Cervical Cancer and Relationship to Survival, Hypoxia, and Apoptosis Clin. Cancer Res., December 1, 2006; 12(23): 6894 - 6900. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Y. Lai and J. R. Grandis Understanding the Presence and Function of Erythropoietin Receptors on Cancer Cells J. Clin. Oncol., October 10, 2006; 24(29): 4675 - 4676. [Full Text] [PDF]
|
|
|
|
|
|
M. Henke, D. Mattern, M. Pepe, C. Bezay, C. Weissenberger, M. Werner, and F. Pajonk Do Erythropoietin Receptors on Cancer Cells Explain Unexpected Clinical Findings? J. Clin. Oncol., October 10, 2006; 24(29): 4708 - 4713. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Elliott, L. Busse, M. B. Bass, H. Lu, I. Sarosi, A. M. Sinclair, C. Spahr, M. Um, G. Van, and C. G. Begley Anti-Epo receptor antibodies do not predict Epo receptor expression Blood, March 1, 2006; 107(5): 1892 - 1895. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. R. LaMontagne, J. Butler, D. J. Marshall, J. Tullai, Z. Gechtman, C. Hall, A. Meshaw, and F. X. Farrell Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Mol. Cancer Ther., February 1, 2006; 5(2): 347 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Hardee, M. O. Arcasoy, K. L. Blackwell, J. P. Kirkpatrick, and M. W. Dewhirst Erythropoietin Biology in Cancer Clin. Cancer Res., January 15, 2006; 12(2): 332 - 339. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Grote, A. L. Yeilding, R. Castillo, D. Butler, E. Fishkin, D. H. Henry, M. DeLeo, K. Fink, and D. J. Sullivan Efficacy and Safety Analysis of Epoetin Alfa in Patients With Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial J. Clin. Oncol., December 20, 2005; 23(36): 9377 - 9386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C. Winter, K. A. Shah, L. Campo, H. Turley, R. Leek, R. J. Corbridge, G. J. Cox, and A. L. Harris Relation of Erythropoietin and Erythropoietin Receptor Expression to Hypoxia and Anemia in Head and Neck Squamous Cell Carcinoma Clin. Cancer Res., November 1, 2005; 11(21): 7614 - 7620. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Stasi, S. Amadori, T. J. Littlewood, E. Terzoli, A. C. Newland, and D. Provan Management of Cancer-Related Anemia with Erythropoietic Agents: Doubts, Certainties, and Concerns Oncologist, August 1, 2005; 10(7): 539 - 554. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Weiss and L. T. Goodnough Anemia of Chronic Disease N. Engl. J. Med., March 10, 2005; 352(10): 1011 - 1023. [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Kumar, G. Acs, D. Fang, M. Herlyn, D. E. Elder, and X. Xu Functional Erythropoietin Autocrine Loop in Melanoma Am. J. Pathol., March 1, 2005; 166(3): 823 - 830. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Dagnon, E. Pacary, F. Commo, M. Antoine, M. Bernaudin, J.-F. Bernaudin, and P. Callard Expression of Erythropoietin and Erythropoietin Receptor in Non-Small Cell Lung Carcinomas Clin. Cancer Res., February 1, 2005; 11(3): 993 - 999. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. O. Arcasoy, K. Amin, S.-C. Chou, Z. A. Haroon, M. Varia, and J. A. Raleigh Erythropoietin and Erythropoietin Receptor Expression in Head and Neck Cancer: Relationship to Tumor Hypoxia Clin. Cancer Res., January 1, 2005; 11(1): 20 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Oikawa, T. Ohbayashi, T. Kiyono, H. Nishi, K. Isaka, A. Umezawa, M. Kuroda, and K. Mukai Expression of a Novel Human Gene, Human Wings Apart-Like (hWAPL), Is Associated with Cervical Carcinogenesis and Tumor Progression Cancer Res., May 15, 2004; 64(10): 3545 - 3549. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
